// App-Quantinova.ai

3058 : Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) tremelimumab (T): CCTG IND226.

Researchers

Presenter

  • Nathalie Daaboul

Principal Investigators

  • Isabelle Gauthier

  • Dongsheng Tu

  • Pamela Brown-Walker

  • Xiaoqun Sun

  • Desiree Hao

  • Rosalyn A. Juergens

  • Penelope Ann Bradbury

  • Mihaela Mates

  • Mustapha Ali Tehfe

  • Christian K. Kollmannsberger

  • Peter Michael Ellis

  • Andrew George Robinson

  • Paul Wheatley-Price

  • Scott Andrew Laurie

  • Lesley Seymour

Medical Centers

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Cancer Centre Of Southeastern Ontario, Kingston, ON, Canada

  • CRCHUM, Montreal, QC, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Kingston General Hospital, Kingston, ON, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON, Canada

  • Queen's University, Kingston, ON, CA

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • N/A

Biomarkers

  • Creatinine

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Ticilimumab

  • Carboplatin

  • Gemcitabine

  • Durvalumab

  • Pemetrexed

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

  • lipase

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02537418

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved